ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is NRX Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 4.40% and Operating profit at -268.76% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.34
2
Flat results in Sep 25
- OPERATING PROFIT(Q) Lowest at USD -4.08 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 5.80%, its profits have risen by 54.2%
4
High Institutional Holdings at 24.98%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 6.65% over the previous quarter.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to NRX Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is NRX Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
NRX Pharmaceuticals, Inc.
50.24%
-0.39
79.27%
S&P 500
30.63%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.40%
EBIT Growth (5y)
-268.76%
EBIT to Interest (avg)
-16.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
-0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.33%
ROCE (avg)
0
ROE (avg)
0.23%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.57
EV to EBIT
-4.55
EV to EBITDA
-4.57
EV to Capital Employed
-3.06
EV to Sales
69.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend22What is working for the Company
NET SALES(9M)
At USD 0.24 MM has Grown at inf%
OPERATING CASH FLOW(Y)
Highest at USD -11.86 MM
RAW MATERIAL COST(Y)
Fallen by -4,298% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 0.15 times
PRE-TAX PROFIT(Q)
Highest at USD 1.25 MM
NET PROFIT(Q)
Highest at USD 1.25 MM
-1What is not working for the Company
OPERATING PROFIT(Q)
Lowest at USD -4.08 MM
Here's what is working for NRX Pharmaceuticals, Inc.
Net Sales
At USD 0.24 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -11.86 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD 1.25 MM has Grown at 141.55%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 1.25 MM has Grown at 141.55%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
Highest at USD 1.25 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 1.25 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 0.15 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -4,298% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for NRX Pharmaceuticals, Inc.
Operating Profit
Lowest at USD -4.08 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
